SC
JAZZ icon

Samlyn Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Samlyn Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-197,925
Closed -$23.8M – 104
2024
Q1 		$23.8M Sell
197,925
-424,251
-68% -$52M 0.4% 71
2023
Q4 		$76.5M Sell
622,176
-736,645
-54% -$91.9M 1.52% 24
2023
Q3 		$176M Buy
1,358,821
+12,591
+0.9% +$1.68M 2.88% 9
2023
Q2 		$167M Buy
1,346,230
+557,605
+71% +$75M 2.83% 6
2023
Q1 		$115M Buy
788,625
+166,789
+27% +$24.7M 2.09% 14
2022
Q4 		$99.1M Sell
621,836
-421,479
-40% -$61.8M 1.94% 16
2022
Q3 		$139M Sell
1,043,315
-160,244
-13% -$24.4M 2.58% 10
2022
Q2 		$188M Buy
1,203,559
+264,146
+28% +$40.7M 3.75% 6
2022
Q1 		$146M Buy
939,413
+283,744
+43% +$41.2M 2.1% 11
2021
Q4 		$83.5M Buy
655,669
+132,383
+25% +$17.4M 1.15% 30
2021
Q3 		$68.1M Buy
523,286
+191,253
+58% +$28.9M 0.91% 33
2021
Q2 		$59M Buy
332,033
+131,614
+66% +$22.8M 0.87% 33
2021
Q1 		$32.9M Buy
+200,419
New +$33M 0.45% 56

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return

Samlyn Capital's JAZZ Position: Q2 2024 in Review

Samlyn Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2024, closing a stake of 197,925 shares — an estimated $23.8M sold.

Samlyn Capital first reported a position in JAZZ in Q1 2021 and held it in 13 quarters. The position peaked at $188M in Q2 2022. 455 funds tracked by Wall St. Rank hold JAZZ as of Q2 2024.

  • Samlyn Capital reported no remaining Jazz Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Samlyn Capital sold 197,925 Jazz Pharmaceuticals shares in Q2 2024, an estimated $23.8M.
  • Samlyn Capital first reported a position in Jazz Pharmaceuticals in Q1 2021 and held it in 13 quarters.
  • Samlyn Capital's Jazz Pharmaceuticals position peaked at $188M in Q2 2022.
  • 455 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2024.

Based on Samlyn Capital's 13F filing for Q2 2024, filed 14 Aug 2024.